Does Rallies show 13F holders for GALT?

Yes. Rallies tracks hedge fund and 13F ownership data for GALT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GALT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GALT. It does not provide personalized investment advice.

GALT (Galectin Therapeutics Inc.) Stock Analysis - Hedge Fund Holdings

Galectin Therapeutics Inc. (GALT) is a publicly traded Healthcare sector company. As of May 21, 2026, GALT trades at $2.21 with a market cap of $144.23M and a P/E ratio of -4.51. GALT moved +6.25% today. Year to date, GALT is -43.04%; over the trailing twelve months it is +71.32%. Its 52-week range spans $0.73 to $7.13. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces GALT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GALT stock?

Hedge funds tracked by Rallies that own GALT include Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Galectin Therapeutics Inc..

GALT Key Metrics

Key financial metrics for GALT
Metric	Value
Price	$2.21
Market Cap	$144.23M
P/E Ratio	-4.51
EPS	$-0.48
Dividend Yield	0.00%
52-Week High	$7.13
52-Week Low	$0.73
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-30.84M
Gross Margin	0.00%

Top Hedge Funds Holding GALT

Mangrove Partners holds 18.78K shares of GALT, changed +0.00% as of Dec 31, 2025.

Latest GALT News

Belapectin trial cuts varices risk by up to 68%; cash runway to April 2027 — Mar 31, 2026
Galectin Therapeutics Appoints Henry Brem, NIH-Funded Neurosurgeon with 416 Publications — Mar 17, 2026

Recent GALT Insider Trades

ELDRED KARY bought 300 (~$810) on Feb 6, 2026.
LEWIS JOEL sold 37.70K (~$134.85K) on Jan 6, 2026.
CALLICUTT JACK W sold 20.35K (~$74.70K) on Jan 6, 2026.

GALT Analyst Consensus

1 analysts cover GALT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.

Common questions about GALT

Who owns GALT stock?: Hedge funds tracked by Rallies that own GALT include Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Galectin Therapeutics Inc..
Does Rallies show 13F holders for GALT?: Yes. Rallies tracks hedge fund and 13F ownership data for GALT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GALT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GALT. It does not provide personalized investment advice.